| Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? | |
| | |
MedLine Citation:
|
PMID: 22212573 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Boceprevir and telaprevir are the first two protease inhibitors available for the treatment of patients infected with hepatitis C virus (HCV) genotype 1. A sustained virological response (SVR) of 70-80% is observed when either of these protease inhibitors is utilized with pegylated interferon (PEG-IFN) and ribavirin (RBV) in treatment naïve patients. Both agents are also highly effective in patients who failed to achieve a SVR during previous treatment with PEG-IFN/RBV. A rapid virological response (RVR) is observed in 56-60% of treatment naïve patients. Patients who achieve a RVR can be treated with a shorter course of therapy (24-28 weeks) and still achieve a SVR rate of 90% or higher. Patients who do not achieve a RVR, those with cirrhosis and certain prior non-responders should be treated for 48 weeks. Although the SVR rates observed with boceprevir and telaprevir are quite similar both globally and within sub-populations, the treatment algorithms for the two agents are unique. The decision of which protease inhibitor to use should assess several factors including the treatment scheme, duration of therapy, adverse event profile, cost and the likelihood of achieving a RVR. The latter is highly dependent upon IFN sensitivity and the IL28B genotype. |
| | |
Authors:
|
Mitchell L Shiffman; Rafael Esteban |
Related Documents
:
|
22967103 - Mutations associated with occult hepatitis b virus infection result in decreased surfac... 10872493 - Infectious complications of 393 peripherally implantable venous access devices in hiv-p... 18482273 - Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic cir... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 32 Suppl 1 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: England |
Other Details:
|
Languages: eng Pagination: 54-60 Citation Subset: IM |
Copyright Information:
|
© 2012 John Wiley & Sons A/S. |
Affiliation:
|
Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA; Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonr...
Next Document: Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon ...